Forensic Analysis · Industrials / Manufacturing / Defense · as of Aug 13, 2026
Chronoscale Holdings Corp (CHRN)
A forensic read on Chronoscale Holdings Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Safe
Financial health
240.8
Distress distance
Clean
Earnings quality
6
Forensic signals
-129.6%
ROE
$3.0B
Market cap
-28.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Chronoscale Holdings Corp earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 240.8, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
288d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 209 to 288 FY2024→FY2025 (against cost of goods sold; inventory +5% vs -29% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-102.1%
FY2025
Return on invested capital.Return on invested capital is -102.1% in the latest fiscal year and rising from -110% — well below its ~9% cost of capital, and it has been across FY2014–FY2025, so reinvested dollars have not been earning their keep.
+18.0%/yr
FY2021–FY2024
Share-count dilution.Diluted share count changed +64% over the last 3 years to FY2024 (+18.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~18.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2021 has been diluted ~39%.
12% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 12% of revenue in FY2025. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 19.3% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
207d DSO
Key fundamentals
Latest Revenue$12.8M
Revenue Growth YoY-28.6%
Net Margin-91.4%
Free Cash Flow-$12.0M
Return on Equity-129.6%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Chronoscale Holdings Corp's actual 10-K/10-Q/8-K filings?
Receivables vs revenue.Days sales outstanding moved from 131 to 207 days FY2024→FY2025 (receivables +1% vs revenue -29%). Receivables are creeping up relative to sales. Across FY2021–FY2025 the day count ran 128 → 131 → 103 → 131 → 207 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Deferred revenue was roughly flat (-19%) over the same period, which doesn't corroborate a benign upfront-billing explanation for the receivables build.
$189,000
FY2020–FY2020
Goodwill impairments.Took $189,000 of goodwill writedowns across 1 year (FY2020 ($189,000)). Writedowns mean past acquisitions underperformed what was paid for them.